Allogeneic CAR-T Dosing Regimen for Efficacy-Toxicity Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The effective dosing of allogeneic chimeric antigen receptor T cells (CAR-T cells) for treating diseases such as cancer is not well established, leading to uncertainties in efficacy and potential toxicity.
Innovation Solution
A therapeutic regimen involving specific dosing schedules and cell numbers of allogeneic CAR-T cells, including initial and subsequent doses, to enhance exposure and persistence, thereby improving efficacy and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of allogeneic CAR-T cells are administered to improve efficacy, then disease treatment effectiveness increases, but toxicity risk increases
Solution Approach 1:
The patent divides the total CAR-T cell dose into multiple separate administrations (e.g., Day 0, Day 15, and Day 30 infusions) rather than delivering all cells at once. This segmentation allows the total effective dose to be achieved while distributing the toxic burden across multiple smaller exposures, thereby improving disease treatment effectiveness while managing toxicity risk
Solution Approach 2:
The patent implements periodic dosing schedules with specific intervals between administrations (e.g., 2-week or 4-week intervals between Day 0 and Day 15, and subsequent intervals to Day 30). This periodic action allows the immune system to partially recover and adapt between doses, maintaining therapeutic effectiveness while reducing cumulative toxicity compared to continuous high-dose administration
2Reliability
If multiple doses of CAR-T cells are administered to increase exposure and persistence, then efficacy improves, but treatment complexity increases
Solution Approach 1:
The patent incorporates preliminary lymphodepletion chemotherapy (e.g., fludarabine and cyclophosphamide) administered before CAR-T cell infusion to clear suppressive immune cells and create a favorable microenvironment. This preliminary action enhances CAR-T cell persistence and efficacy without requiring complex real-time adjustments during the actual cell administration process
Solution Approach 2:
The patent systematically varies dosing parameters including cell dose amounts (e.g., 1×10^6 to 1×10^8 cells per infusion), timing intervals (e.g., 2-week or 4-week schedules), and lymphodepletion regimens. These controlled parameter changes optimize the balance between efficacy and complexity by establishing standardized protocols that can be replicated without requiring complex adaptive decision-making
Data Source
AI summary
The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.